The changing role of surgery in metastatic non-seminomatous germ cell tumour. by Cassidy, J. et al.
Br. J. Cancer (1992), 65, 127 129 t~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ Macmillan PressLtd., 1992~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
The changing role of surgery in metastatic non-seminomatous germ cell
tumour
J. Cassidy', C.R. Lewis', S.B. Kaye' & D. Kirk2
CRC Departments of'Medicine Oncology and 2Urology, Western Infirmary, Dumbarton Road, Glasgow GIl 6NT, UK.
Summary In the last 2 years (1989-1990) we have treated a total of 53 patients with metastatic non-
seminomatous germ cell tumours (teratoma). In ten cases surgery to remove residual abdominal masses was
required on completion of chemotherapy and normalisation of tumour markers (HCG and AFP). In a further
three patients with large intra-abdominal masses and little or no other sites of disease surgery was performed
as a therapeutic intervention, in the context of plateauing or rising tumour markers despite intensive
chemotherapy. In all three, this approach resulted in a rapid fall in tumour markers, and following further
chemotherapy all three remain disease free at 7, 12 and 25 months. For this small sub-group of patient failing
to respond to chemotherapy who have resectable lesions, interventional surgery should be considered as part
of a combined approach to treatment.
The introduction of cisplatin into chemotherapy for non-
seminomatous germ cell tumours (teratoma) was responsible
for a dramatic improvement in the prognosis (Einhorn &
Donohue, 1977). Currently the overall cure rate for this
tumour is of the order of 90% (Loehrer et al., 1988),
although for patients with the most advanced metastatic
disease, the prospect of cure is somewhat lower, at approx-
imately 40-70% (Lewis et al., 1991). The optimal manage-
ment strategy for these patients with large volume metastatic
disease has not yet been fully defined.
In general, since early debulking has been shown not to
improve prognosis (Javadpour et al., 1982), surgery has been
reserved for removal of residual masses on completion of
chemotherapy. This may involve removal of retroperitoneal
or pulmonary lesions, or a combination of both. Subsequent
histological examination reveals mature teratoma, necrotic
tissue, or occasionally residual viable tumour in these
resected masses. Surgical resection is generally performed in
the context of normal tumour markers (i.e. alpha-feto protein
and human chorionic gonadotrophin). The use of planned
early resection of tumour has been reported (Pizzocaro et al.,
1985) to convert some partial responders to three cycles of
chemotherapy into complete responders following further
chemotherapy, but in this case surgery was performed at a
time when tumour markers were falling indicating continued
response to chemotherapy. The use of 'interventional' surgery
to salvage patients with bulky lesions and plateauing or
rising markers was reported in four out of 100 cases (Logo-
thetis et al., 1986) with a successful outcome in three
patients. However this approach is not standard practice in
the UK and these patients typically have a very poor prog-
nosis.
In this paper we present the results of 'interventional'
surgery in three patients and propose new guidelines for
consideration of surgery in this selected group of poor prog-
nosis patients.
Patients and methods
In the 2 years 1989-1990 we treated 53 patients with metas-
tatic teratoma. Thirteen patients required surgical excision of
abdominal masses. In ten, surgery was performed after
successful completion of a planned regimen ofchemotherapy,
and in the presence of normal tumour markers. In three
patients surgery was used as a therapeutic intervention in the
context of rising or plateauing tumour markers.
The following abbreviations are used for chemotherapy
regimens:-
BOP cisplatin
vincristine
bleomycin
repeated on
50mgm-2
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30mg
days 1, 10 and
day 1 and 2
day 1
day 1
21.
VIP etoposide 100 mg m-2 day
ifosfamide 1 g m2
cisplatin 20 mg m-2
days 1-5 on weeks 6, 9 and 12.
BEP bleomycin 30 mg day
etoposide 120 mg m-2 day
cisplatin 20 mg m-2 day
on a three weekly schedule.
POM(B) cisplatin
vincristine
methotrexate
bleomycin
lOOmgm-2
1 mgm-2
300mgm-2
15 mg
ACE actinomycin D 0.5 mg
cyclophos- 500 mg m-2
phamide
etoposide 100 mg m2
day
day
day
day:
day:
day
day:
(s 1, 3 and 5
2
rs 1, 3 and 5
rs 1-5
4
1
1
s 2 and 3
s 3, 4 and 5
s 1 to 5
Case I
A 28 year old man presented with left sided testicular pain
and baclkache. A left orchidopexy had been performed some
17 years previously at the same time as a right orchidectomy
for torsion. Pre-operative markers were AFP 37,000 and
HCG 15; a CT scan revealed a huge abdominal mass, but no
other disease above the diaphragm. A left inguinal orchidec-
tomy was performed and histology confirmed a diagnosis of
malignant teratoma intermediate. Chemotherapy using an
intensive platinum based regimen known as BOP/VIP (Lewis
et al., 1991) was commenced on 26.11.88. Figure 1 illustrates
the marker response to chemotherapy with evident failure to
respond noted around the end of January 1989. Laparotomy
was undertaken on 9.2.89, and a large mass which was
displacing the aorta was removed with complete macroscopic
clearance of tumour. Histology revealed this mass to be
mainly necrotic, but areas of viable tumour were identified
within the capsule. The serum AFP started to fall again
post-operatively and continued to fall during three further
cycles of VIP chemotherapy. The patient is alive and disease
free just over 2 years later with no further therapy.
Case 2
A 22 year old male student presented with a 2 month history
of abdominal pain and was found to have a large palpable
abdominal mass. Laparotomy was performed and a large
Correspondence: J. Cassidy.
Received 12 July 1991; and in revised form 12 September 1991.
0 Macmillan Press Ltd., 1992 Br. J. Cancer (1992), 65, 127-129128 J. CASSIDY et al.
AFP
BOP VIP
BOPBOP BEP VIP VIP VIP
IstS X I I I
5297 and HCG6. He was commenced on BEP chemotherapy
on 10.5.90, the first cycle of which was complicated by
neutropenia, staphyloccal septicaemia, and an episode of sep-
tic arthritis. This necessitated a delay in administration of
cycle 2, further neutropenia with this cycle dictated a dose
reduction of 25% in etoposide doses for cycles 3 and 4. The
pattern of fall in AFP with relation to chemotherapy is
shown in Figure 3. In late July 1990 the AFP level plateaued
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Figure 1 Fall in AFP with time in patient 1.
mass of para-aortic lymph nodes identified; this was biopsied
but felt to be non-resectable by the referring surgeon. Histo-
logy confirmed malignant teratoma intermediate and tumour
markers were HCG 15,280 and AFP 18,379. The left testis
was felt to be abnormal, but ultrasound examination failed
to define a mass lesion. A CT scan revealed a 12 cm diameter
para-aortic mass, but no disease above the diaphragm. He
commenced on BEP chemotherapy with an initially good
marker response as shown in Figure 2. In early April 1990
his tumour markers plateaued and a repeat scan showed the
para-aortic mass to be of the same overall dimensions but
multiple cystic spaces had appeared within the lump. Lapa-
rotomy on 15.5.90 revealed a mass in the left paracolic gutter
which extended upwards and anteriorly to involve the duo-
denum with inferior extension to surround the lower third of
the aorta. This mass was dissected free of all structures and
removed with macroscopic clearance of tumour. Multiple
blind biopsies were obtained from around the edges of the
resection and a left orchidectomy performed. Histology of
the removed tissue showed malignant teratoma differentiated
with small foci of malignant teratoma intermediate; some of
the biopsies showed encroachment on excision margins. The
testis was histologically normal. Following this operation his
tumour markers fell to within the normal range but two
further cycles of POMB-ACE chemotherapy were administer-
ed in view of the pathological findings. He remains well with
no evidence or relapse, 12 months after completing treat-
ment.
Case 3
A 28 year old male publican presented with a history of two
episodes of left testicular swelling over the preceding 4
months. These had both been treated with antibiotics on a
presumptive diagnosis of orchitis. On presentation he com-
plained of abdominal pain, had a 6 x 3 cm left testicular
mass confirmed by ultrasound examination and CT scan
revealed a 3.8 x 3.6 cm mediastinal mass, an isolated lung
secondary and a 12.7 x 13.3 cm para-aortic mass. A needle
biopsy of the mass yielded a pathological diagnosis of malig-
nant teratoma differentiated, and tumour markers were AFP
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and at that stage a CT scan showed a residual 12 x 13 cm
abdominal mass, as well as a residual lesion in the media-
stinum and a single lung metastasis. Despite the presence of
lesions above the diaphragm, a laparotomy was performed
on 16.08.90. A large mass occupying the left para-colic gutter
causing displacement of the kidney and surrounding the
aorta was removed with complete macroscopic clearance of
tumour. A left orchidectomy was also performed, and both
the testis and the mass showed histological evidence of cystic
areas with lining epithelium, smooth muscle and foci of
cartilage formation consistent with differentiated malignant
teratoma. Further chemotherapy in the form of two cycles of
POMB-ACE was given post-operatively with normalisation
of serum AFP. Thoracotomy was performed on 29.01.91 to
remove a mass of residual differentiated teratoma from the
posterior mediastinum. As this operation the single lung
lesion still visible on CT scan was impalpable. The serum
AFP has remained normal with no clinical evidence of
relapse 7 months after completing therapy.
Discussion
As a general rule in cancer therapy, the greater the number
of tumour cells present the more likely is mutation to or
selection of a drug resistant phenotype during therapy. It
therefore seems reasonable to expect any drug resistant cells
to arise in the largest tumour masses. In all three patients
detailed in this paper the response to chemotherapy was
intially satisfactory as judged by falling markers, but this
could not be maintained with repeated cycles of treatment,
implying a degree of acquired cytotoxic drug resistance. In
this situation the clinician is faced with a number of difficult
decisions; can more intensive chemotherapy be safely deliver-
ed? Can different agents be substituted with a realistic
expectation of cure? Should a purely palliative approach be
adopted? In these patients we decided to remove surgically
the largest mass, which should contain the resistant fraction
of cells. The evident success of this intervention is witnessed
by the fall in tumour markers that occurred in all cases even
before further chemotherapy was given. It is unclear whether
the cells removed were resistant because of intrinsic cellular
mechanisms or more simply due to problems of drug pene-
tration into large necrotic masses of tumour. Nevertheless,
each of our patients was converted from an apparently drug
resistant phase into a curable situation by the use of judi-
ciously timed radical surgery.
An alternative explanation for this pattern of tumour
marker fall in these patients is suggested in the recent pub-
lication (Van der Gast et al., 1991) detailing two patients in
whom cystic differentation occurred within the tumour with
formation of cyst fluid rich in markers thereby forming a
reservoir. The apparent resistance of these patients to chemo-
therapy was therefore fallacious. In cases 2 and 3 of this
report the resected tumours did show mainly differentiated
teratoma, but in both cases cells were present which stained
for AFP using immunohistochemical methods and these are
assumed to be the source of serum markers rather than any
cyst reservoir ofmarkers as in the cases described by Van der
Gast et al. (1991).
The traditional place of surgery in teratoma is in the initial
diagnosis, and in the subsequent resection of post-chemo-
therapy residual masses (Einhorn et al., 1981). Planned initial
'debulking' surgery proved to be of no value in one random-
ised study (Javadpour et al., 1982), although surgery per-
formed after three cycles of treatment in responding patients
has perhaps contributed to the excellent results in one non-
randomised series of patients with advanced disease (Pizza-
caro et al., 1985). A similar treatment policy to that
described in this paper was pursued by Logothetis et al.
(1986) in four patients. In the light of our experience we
would advocate that teratoma patients with very large masses
(particularly abdominal) but small volume disease elsewhere
be considered for surgical removal of the largest masses in
the specific situation of attentuation of chemotherapy re-
sponse as judged by serial marker estimations and CT scann-
ing. However this must be carefully considered as inevitably
not all patients will have a successful outcome (Logothetis et
al., 1986) and surgical intervention might delay the introduc-
tion of alternative (perhaps more effective) chemotherapy.
Over a 2 year period in our centre, these circumstances
became evident in 6% ofthe patients requiring chemotherapy
for metastatic teratoma. Such an approach requires exper-
ience in retroperitoneal surgery on behalf of the surgeon
involved and careful timing of surgery with the early involve-
ment of the surgical team in discussions of treatment plans.
In a small subgroup ofpatients, this combined approach may
well prove to have curative potential.
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